USC Norris Comprehensive Cancer Center

ACCELERATING PROMISING ONCOLOGY THERAPEUTICS INTO THE CLINIC THROUGH COLLABORATIVE DRUG DEVELOPMENT

About the CCDD at USC Norris

USC Norris Comprehensive Cancer Center (USC Norris) is pleased to launch the Rosalie and Harold Rae Brown Center for Cancer Drug Development (CCDD) with a generous gift from the Rosalie and Harold Rae Brown Foundation.  The CCDD employs an integrated academic-industry focused management model to engage investigators from different disciplines, collapse gaps in expertise, resources, and funding, and ensure that programs have a high likelihood of progressing to late Pre-Clinical stage development and submission of an Investigational New Drug (IND) application. Initial projects will be sharply focused on cancers that disproportionately affect members of the community for whom there are dramatic ethnic and racial disparities, such as breast cancer, prostate cancer and colorectal cancer, and blood cancers.

For USC Norris Cancer Center Members

The Rosalie and Harold Rae Brown Center for Cancer Drug Development (CCDD) can help accelerate your research project into new therapies for patients. Contact us to learn what makes a good drug development project, how to apply for project support, understand industry areas of focus, or how to attract an industry partner.

CCDD Process

How to Submit Targets to CCDD

Please contact Melissa Rodgers from the USC MESH Academy Business Development and Industry Relations team.

For Industry

The Rosalie and Harold Rae Brown Center for Cancer Drug Development (CCDD) utilizes an integrated academic-industry management model to engage investigators from different disciplines, collapse gaps in expertise, resources, and funding, and ensure that programs have a high likelihood of progressing to Pre-Clinical stage development. 

Contact us to:

      • Connect to a highly collaborative, NCI-designated comprehensive cancer center, clinical trial expertise, and one of the most diverse patient populations in the country.
      • Access to innovative preclinical drug candidates that can be expedited to IND readiness.
      • Co-create partnering strategies that are mutually beneficial, de-risk projects, and accelerate a path to the clinic for patients.
      • Learn more about the CCDD Partnering Zone

Please contact Vasiliki Anest, Business Director.

Caryn Lerman, PhD
Director, USC Norris Comprehensive Cancer Center
Associate Dean for Cancer Programs
H. Leslie and Elaine S. Hoffman Chair in Cancer Research

“This gift will have an immediate impact by transforming USC Norris discoveries of the underlying causes of cancer and disease progression into new treatments and clinical trials for our patients.”

CCDD Scope

CCDD Goals

    • Identify high potential projects and support the development of Oncology therapeutics through strategic alliances with expert drug development partners. 
    • Provide specialized concierge service through the MESH Academy to USC researchers and External Partners that will:  
      • Grow a community of innovative drug developers. 
      • Build and manage relationships and strategic alliances with industry and venture capital.
      • Formulate partnering strategies that will de-risk projects and accelerate path to patients.
      • Provide one-on-one project consultation and training materials pertaining to science and business considerations unique to drug development. 
    • Leverage expertise across USC and enable access to existing core facilities to support drug discovery activities. 

Contact Information

For more information on the CCDD review process, please contact Melissa Rodgers or Camilo Ansarah-Sobrinho from the USC MESH Academy Business Development and Industry Relations team.   

For general questions or interests in partnering with the CCDD, please contact Vasiliki Anest, Business Director. 

 To learn more about giving to USC Norris, please contact Minhaal M. Nathani, Executive Director of Development, at Minhaal.Nathani@med.usc.edu

CCDD Team

Screen Shot 2020-11-03 at 2.44.23 PM

Caryn Lerman, PhD

Director, USC Norris Comprehensive Cancer Center
Associate Dean for Cancer Programs
H. Leslie and Elaine S. Hoffman Chair in Cancer Research
clerman@usc.edu

HJL

Heinz-Josef Lenz, MD

CCDD: Co-Director
lenz@usc.edu

Provost Professor of Neurology, Biomedical Engineering and Biological Sciences Steve Kay photographed during March 2018 at the USC Michelson Center for Convergent Bioscience. (Photo/NoŽ Montes)

Steve Kay, PhD

CCDD: Co-Director
stevekay@usc.edu

Vasiliki-Anest

Vasiliki Anest, PhD

CCDD: Business Director
Vasiliki.Anest@med.usc.edu

Camilo Ansarah

Camilo Ansarah-Sobrinho, PhD

Business Development and Industry Relations
Camilo.ansarah@med.usc.edu

MRodgers

Melissa Rodgers, PhD

Busines Development and Industry Relations
rodgersm@usc.edu

External Advisory Committee

Michael-Jackson

Michael Jackson, PhD

Senior Vice President of Drug Development, Sanford Burnham Prebys Medical Discovery Institute

Mark_Namchuk

Mark Namchuk, PhD

Executive Director, Therapeutics Translation of Harvard Medical School

itoudjarska-tiny

Iva Toudjarska, PhD, MBA

Vice President, Portfolio Operations, Xontogeny

Stefan

Stefan Scherer, MD, PhD

CEO, 3TBiosciences, Inc.